Galectin Therapeutics Inc Sustainability Reports
Galectin Therapeutics Inc. is a clinical-stage biotechnology company focused on the research and development of therapies for fibrotic liver disease and cancer. The company applies its expertise in galectin science to develop proprietary carbohydrate-based therapeutics, notably its lead candidate belapectin.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 5299004HFYSAZM2ALW85
FIGI: BBG001S9NYW2
4 reports from 2012 to 2024
